Who We Are
Precefi was founded by a team of biotech industry veterans with deep experience at companies like Allergan, Regeneron, AstraZeneca, and Incyte — and a track record that includes contributions to the development and approval of Botox®, Eylea®, Kybella®, Opzelura®, and more.
We built Precefi to solve a fundamental problem in clinical research: sponsors shouldn’t have to manage dozens of relationships to run a single trial. Our network of KOL-led dermatology and ophthalmology sites operates under one contract and one price, with integrated biomarker services, our Appiell virtual platform, and a team that understands drug development from the inside out.
We are a site network built on decades of experience, leading KOLs, and a commitment to redefining clinical research.
Leadership Team
Fauad Hasan
Earlier in his career, Fauad held leadership roles at Allergan, contributing to global development strategy for major neurotoxin and ophthalmology franchises, including Botox®. He began his industry career at Regeneron, supporting early work on Eylea® and Dupixent®, and at Baxter (now Takeda), where he led engineering and manufacturing initiatives. He is also an inventor of single-use bioreactor technology. Fauad holds multiple patents (bioprocessing/drug development), and his research has been published in peer-reviewed journals and scientific book chapters. Following Bonti’s exit, Fauad has remained active as a board chair, advisor, investor, and co-founder of NewCos, across therapeutics, clinical research, and medical aesthetics. He currently supports multiple biotech and medtech companies globally and advises investment funds on scientific and technical diligence. Fauad also serves on the board of Octane, a Southern California based life sciences accelerator, as well as on the advisory boards of Aesthetic Tech Forum, Medical Aesthetics Injectable Summit, and Aesthetics Innovation Summit.
Richard Panico
Ehsan Sadri, MD
Ehsan Sadri, M.D. FACS is CEO and Founder of Visionary Eye Institute with locations to serve patients in Newport Beach, Santa Ana, Orange and more locations to come. He is also General Partner, and co-founder of Visionary Ventures Fund (Visionaryvc.com).
Ehsan Sadri, M.D., FACS, FAAO is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries. He is trained in the most progressive ocular surgical techniques including cataract surgery, phakic intraocular lenses, LASIK, PRK, refractive lensectomy, and AK. Dr. Ehsan Sadri has performed thousands of eye surgeries utilizing advanced techniques for treatment of myopia (nearsightedness), hyperopia (farsightedness), and astigmatism.
Dr. Ehsan Sadri is well regarded as a thought leader and an active speaker at many Ophthalmology conferences where he teaches other eye surgeons the latest techniques for vision correction and preservation.
Dr. Sadri received his undergraduate degree in biochemistry and Spanish from the University of California, Davis. He obtained his medical education at the University of Michigan in Ann Arbor. There he completed a prestigious Fight for Sight fellowship in retina and glaucoma research at the highly esteemed Kellogg Eye Center. He completed his internship at the Arrowhead Regional Medical Center affiliated with UC Irvine. Dr. Sadri completed his ophthalmology residency at the University of Maryland in Baltimore and his glaucoma and cataract fellowship at the University of California, Irvine. Dr. Sadri’s research has been presented at national ophthalmologic meetings and published medical journals. He has performed numerous clinical trials involving new medications for glaucoma and innovative laser treatments.
His specialties include: Premium IOL and complex cataract surgeries; glaucoma, shunt and Minimally Invasive Glaucoma Surgeries (MIGS), and Oculoplastics.
Dr. Sadri is fluent in Spanish and Farsi.
Patricia Walker, MD PhD
As Chief Medical Officer at Kythera Biopharmaceuticals, Dr. Walker led the clinical development of ATX-101 (deoxycholic acid) for submental fat reduction, culminating in a unanimous 17-0 FDA advisory committee vote in favor of approval. As President and Chief Scientific Officer at Brickell Bio, she advanced sofpironium bromide from preclinical development through Phase 3 for hyperhidrosis. Earlier in her career, she served as Executive Vice President and Chief Scientific Officer at Allergan Medical Aesthetics, overseeing clinical programs across dermal fillers, breast implants, and obesity devices.
Dr. Walker’s regulatory track record includes more than 60 successful filings across PMAs, INDs, NDAs, BLAs, and international submissions. She has authored over 60 peer-reviewed publications and holds active board positions including Merz Aesthetics Board and Botanix Pharmaceuticals. She completed her M.D./Ph.D. at the University of Iowa College of Medicine and a research fellowship at the National Institutes of Health, Dermatology Branch.
“Experience isn’t just our history, it’s what we deliver on every trial.”
Richard Panico – CEO Precefi
